Osteoporosis is a complex, multifactorial chronic disorder characterized by low bone mass, microarchitectural deterioration of bone tissue leading to enhanced bone fragility resulting in increased fracture risk and also a major cause of morbidity and mortality [1]. Although exact numbers are not available, with increasing longevity of the Indian population, it is now being realized that osteoporotic fractures are a major cause of morbidity and mortality in the aging population [2,3]. The occurrence of osteoporosis is increased with the age especially in postmenopausal women because estrogen deficiency is the most common cause of hormone related osteoporosis [4]. The most frequent and important of the related fractures are those of the proximal femur, vertebrae and distal forearm, but fractures commonly occur at many other locations as well. It has been recognized for over a century that hip fractures are a manifestation of osteoporosis in the elderly and vertebral fractures have been virtually synonymous with postmenopausal osteoporosis [5]. The fracture risk increases exponentially with each decade in age over 50. Residents of nursing homes may be at an even higher risk of fracture. Both men and women lose bone as they age. However, women have accelerated bone loss surrounding menopause due to loss of estrogen. Men have some protection from osteoporosis owing to their large bone mass and size and the absence of menopause [6]. The process of bone remodeling that maintains a healthy skeleton may be considered as a preventive maintenance program, frequently removing older bone and replacing it with new bone. Bone loss occurs when this balance is altered; resulting in greater bone removal than replacement thereby individual trabecular plates of bone are lost, leaving an architecturally weakened structure with significantly reduced mass [7]. Bone resorption markers reflect the level of osteoclastic activity in the bone-remodeling process. Accelerated osteoclastic activity increases bone turnover and is associated with low bone mass in both pre- and post-menopausal women. Elevated levels of resorption markers indicate increased osteoclastic activity and a higher risk for osteoporotic hip fracture, independent of bone mineral density (BMD) [8]. The management of osteoporosis includes preventive therapy where maximizing the bone mass during the formative years and then maintaining bone mass once peak bone mass has been achieved. Among these antiresorptive agents selective estrogen receptor modulators are compounds that bind with estrogen receptors and exhibit estrogen action in some tissues and anti-estrogen action in other tissues [9]. The hormone replacement therapy, initiated at the onset of menopause, has been demonstrated in numerous studies to be capable of improving menopause-related symptoms, while at the same time preventing the loss of bone mass associated with menopause. Nevertheless, due to its side effects, particularly relevant among which is the potential risk of developing breast cancer, the use of this type of medication should not be anticipated as the first-line therapy for osteoporosis [10]. The phytoestrogens, which are found in plants naturally, help to improve few problems that are associated with menopause. They have been investigated to find out their potential benefits in caring age-related, habitual and hormonal conditions. The genus *Morinda* (Rubiaceae) including the species *Morinda citrifolia* is made up of around 80 species. *M. citrifolia* is commonly known as Indian mulberry or noni. The noni plant has been found to contain amino acids, anthraquinones, fatty acids, flavonoids, sterois, and terpenoids. It also serves as a good source of iron, calcium and other minerals which are effective in reducing pain in osteoporosis and in the reduction of swelling in rheumatoid arthritis [11]. The noni seeds are rich in anthraquinones and calcium, and tartrate resistant acid phosphatase and showed significant effects (p<0.0001). The femur bone strength assessed by three-point bending test showed improved bone strength in physcion treated rats, and this was supported by enhanced bone mineral density (p<0.05). The ash parameters of femur bone studied from physcion treated rats exhibited a significant (p<0.0001) value of ash weight followed by ash calcium content. Further; femur bone histological examination revealed the protective effect of the compound physcion (100 mg/kg) against OVX-induced bone loss in rats, where it showed mineralization of trabecular spaces, improved bone compactness thereby intact bone architecture. This study concludes that the isolated anthraquinone physcion had a preventive effect against OVX-induced bone loss in rats.

**INTRODUCTION**

**Methods:** All the rats were divided into 4 groups (n=6 each). Group I (sham control) received vehicle, p.o., Group II OVX control (vehicle, p.o.), Group III was OVX-standard raloxifene (5.4 mg/kg, p.o.), and Group IV was OVX-Physcion (100 mg/kg, p.o.) for 90 days.

**Results:** The daily oral administration of isolated compound physcion (100 mg/kg) for 12 weeks to the rats prevented OVX-induced osteoporosis. This was examined by serum biomarkers suc such as alkaline phosphatase, calcium, and tartrate resistant acid phosphatase and showed significant effects (p<0.0001). The femur bone strength assessed by three-point bending test showed improved bone strength in physcion treated rats, and this was supported by enhanced bone mineral density (p<0.05). The ash parameters of femur bone studied from physcion treated rats exhibited a significant (p<0.0001) value of ash weight followed by ash calcium content. Further; femur bone histological examination revealed the protective effect of the compound physcion (100 mg/kg) against OVX-induced bone loss in rats, where it showed mineralization of trabecular spaces, improved bone compactness thereby intact bone architecture.

**Conclusion:** This study concludes that the isolated anthraquinone physcion had a preventive effect against OVX-induced bone loss in rats.

**Keywords:** *Morinda citrifolia*, Physcion, Osteoporosis, Bone mineral density, Ash mineral content.

© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2016.v9i5.13269

**ABSTRACT**

**Objectives:** This study was designed to investigate the antosteoporotic activity of isolated anthraquinones from *Morinda citrifolia* fruit extract in ovariectomy (OVX) induced osteoporotic rats.

**Methods:** All the rats were divided into 4 groups (n=6 each). Group I (sham control) received vehicle, p.o., Group II OVX control (vehicle, p.o.), Group III was OVX-standard raloxifene (5.4 mg/kg, p.o.), and Group IV was OVX-Physcion (100 mg/kg, p.o.) for 90 days.

**Results:** The daily oral administration of isolated compound physcion (100 mg/kg) for 12 weeks to the rats prevented OVX-induced osteoporosis. This was examined by serum biomarkers suc such as alkaline phosphatase, calcium, and tartrate resistant acid phosphatase and showed significant effects (p<0.0001). The femur bone strength assessed by three-point bending test showed improved bone strength in physcion treated rats, and this was supported by enhanced bone mineral density (p<0.05). The ash parameters of femur bone studied from physcion treated rats exhibited a significant (p<0.0001) value of ash weight followed by ash calcium content. Further; femur bone histological examination revealed the protective effect of the compound physcion (100 mg/kg) against OVX-induced bone loss in rats, where it showed mineralization of trabecular spaces, improved bone compactness thereby intact bone architecture.

**Conclusion:** This study concludes that the isolated anthraquinone physcion had a preventive effect against OVX-induced bone loss in rats.

**Keywords:** *Morinda citrifolia*, Physcion, Osteoporosis, Bone mineral density, Ash mineral content.
no. 600/PO/Ere/S/02/CPCSEA). All the animals were acclimatized for 7 days under standard husbandry conditions, i.e., room temperature of 25 ± 1°C, relative humidity 45-55%. The animals had free access to standard rat pellet (Amruth Animal Feeds Pvt. Ltd., Bengaluru, India), with water supplied ad libitum under strict hygienic conditions. The experimental protocols were approved by the Institutional Animal Ethics Committee (PESCP/IAEC/09/2010, Dated: 14/12/2010) and conducted according to CPCSEA guidelines, Government of India.

Acute oral toxicity (AOT)
The AOT was performed according to the OECD guidelines 423. In brief, the albino female mice of three groups (n=3) were used. Animals of all the groups were fasted for 3–4 hrs before the test and administered 50, 300 and 2000 mg/kg body weight of freshly prepared M. citrifolia fruit extract. Then, the animals were observed immediately and after 30 minutes, periodically during the first 24 hrs, with special attention given during the first 4 hrs, and daily thereafter, for a total of 14 days. At the end of the 14th day, the animals were sacrificed with anesthetic overdose and dissected for examination of vital organs [12].

Drugs and chemicals
Raloxifene hydrochloride tablets (Dr. Reddy’s, Hyderabad, India), ketamine hydrochloride injection (Neon Laboratories Ltd.), xylazine injection (Indian Immunologicals Ltd., Andhra Pradesh, India), calcium and alkaline phosphatase (ALP) kits (Erba Mannheim, Badly, India), tastrate resistant acid phosphatase (TRAP) kit (Accurex Biomedical Pvt. Ltd., Mumbai, India), and all other chemicals and reagents were of analytical grade purchased from SD Fine-Chem Ltd., Mumbai, India.

Plant material
Fresh fruits of M. citrifolia were collected from Arvind Trading Company, Bengaluru, in the month of August. The plant was identified and authenticated by Dr KP Sreenath, taxonomist Department Botany, Bengaluru University, India.

Isolation and identification of the compound
The dried powdered fruits were refluxed with ethanol (70%) for 4 days. The same process was repeated for three times, and then the solvent was concentrated under vacuum and filtered. The major constituents were identified by optimization of thin layer chromatography (TLC). The plates were scanned at 254 and 366 nm using petroleum ether: Ethyl acetate (8:2) solvent system [13]. About 60 g of extract was chromatographed on silica gel column (60-120 mesh, 600 g) and successively eluted with an increase in their polarity. The fractions were collected, and each fraction was spotted on pre-coated silica gel plate (Merk-F6254, 0.25 mm thick) and eluted according to their polarity. Fractions with sufficient yield were selected for further studies. Fraction 11 showed a single spot on the TLC. The structure of the isolated compound was elucidated on the basis of nuclear magnetic resonance (NMR) and mass spectra analysis (Fig. 1) [14].

Induction of osteoporosis by ovariectomy (OVX)

Surgical procedure
After 1 week of acclimatization, the rats to be operated were anesthetized with ketamine (80 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). In all the groups, operation was made after placing animal on its ventral surface. The place and used surgical equipment were aseptically cleaned. OVX was preceded by a midline dorsal skin incision, 3 cm long, approximately half way between the middle of the back and the base of the tail. Incisions of the muscles were made bilaterally. After peritoneal cavity was accessed, the ovary was found surrounded by a variable amount of fat. To avoid bleeding, ligation of the blood vessels was done before removal of the ovary. The connection between fallopian tube and the ureteral horn was cut, and the ovary was excised. Whereas in sham operated rats, only ovaries were exposed but not excised. Muscle incision was sutured with absorbable catgut, whereas skin wounds were closed bilaterally with three single catgut sutures. Operated animals were given prophylactic amoxicillin (25 mg/kg, i.p.) for 4 days and povidone-iodine solution was applied locally. After surgery, the rats were housed individually in polyurethane cages for a period of 1-week to allow recovery and then re-grouped in their home cages [15].

Experimental design
Female Sprague-Dawley rats of 6 months old weighing 150-200 g were used in the study. All the operated rats were divided into 5 groups (n=6) and treated for 90 days.
• Group I - Sham operated (vehicle)
• Group II - OVX control (vehicle)
• Group III - OVX + raloxifene (5.4 mg/kg, p.o.)
• Group IV- Physcion (100 mg/kg, p.o.)

Measurement of length and weight of femur bone
The femur bones were cleaned from the surrounding tissues then dried, and the length which is defined as the distance between greater trochanter and medial condyle was measured using a digital caliper (Mitutoyo corp., Japan). Then, the bones were kept in an oven and dried at 110°C for 8 hrs and the weights of the dried bones were determined using a digital weighing balance (Sartorius AG) [16].

Serum biochemical parameters
The calcium and ALP were estimated using Erba diagnostic kits, whereas, TRAP was estimated using accurex diagnostic kit.

Three-point bending test
The isolated femur bones were assessed for their biomechanical strength using three-point bending apparatus. The sample was fixed horizontally between the mounting slots of the apparatus (Zwick/ Roell 2005) against the cylindrical stoppers of 5 mm diameter where the cylindrical stoppers support the bone at ends which were rigidly fixed to the frame of the apparatus. The load was applied exactly at the center of the bone using a steel wire of 0.5 mm diameter passing horizontally. The load was varied gradually from 5 N to maximum breaking point, and the sample values were showed by increments of small steps. Then, the corresponding deflection of the sample was evaluated using a laser displacement sensor through a data acquisition system [17].

Measurement of BMD
The BMD of rat femur was assessed by fluid displacement method using archimedes’ principle [17].

Determination of bone ash weight and mineral content
Femur bone ash was obtained using muffle furnace (700°C for 6 hrs) and dissolved in 0.1 mol/L hydrogen chloride solution. Bone calcium was measured by a ultraviolet-visible spectrophotometer (RMS-BCA 201) [17,18].
Results and discussion

The fraction 11 of ethanolic fruit extract of M. citrifolia yielded a yellow colored active compound which was confirmed with its NMR and mass spectra values. These data led to the identification of a well-known compound, physcion, i.e., 1,8-dihydroxy-3-methoxy-6-methylanthraquinone (C₁₂H₁₀O₅) with a molecular weight of 284.

Effect of physcion on change in body weight

The OVX resulted in significant (p<0.0001) increase in body weight and mass spectra values. These data led to the identification of a well-known compound, physcion, i.e., 1,8-dihydroxy-3-methoxy-6-methylanthraquinone (C₁₂H₁₀O₅) with a molecular weight of 284.

Table 1: Effect of physcion on change in body weight

| Serial number | Groups (n=6)     | Change in body weight (g) | Average increase in body weight (g) |
|---------------|------------------|---------------------------|-------------------------------------|
| 1             | Sham operated    | 207.00±6.68               | 207.00±6.68                         |
| 2             | OVX control      | 200.70±7.33               | 200.70±7.33                         |
| 3             | Raloxifene (5.4 mg/kg) | 204.00±6.21          | 204.00±6.21                         |
| 4             | Physcion (100 mg/kg) | 207.3±5.43               | 207.3±5.43                          |

Values are in mean±SEM (n=6). One-way ANOVA followed by Tukey-Kramer multiple comparison test ***p<0.0001.

Effect of physcion on femur length and weight

Table 2: Effect of physcion on femur length and weight

| Serial number | Groups (n=6)     | Femur length (mm) | Femur weight (g) |
|---------------|------------------|-------------------|------------------|
| 1             | Sham operated    | 34.86±0.257       | 0.611±0.005      |
| 2             | OVX control      | 35.23±0.268       | 0.666±0.005      |
| 3             | Raloxifene (5.4 mg/kg) | 35.41±0.370      | 0.666±0.005      |
| 4             | Physcion (100 mg/kg) | 34.81±0.249       | 0.675±0.005      |

Values are in mean±SEM (n=6). One-way ANOVA followed by Tukey-Kramer multiple comparison test SEM: Standard error of the mean, OVX: Ovariectomy

Histopathology

The femur bone was fixed (10% phosphate formalin buffer) for 24 hrs, decalcified in ethylenediaminetetraacetic acid (15%) for 4 days, dehydrated in alcohol, cleared in xylol, and embedded in paraffin wax (56-58°C mp). Sections (6 mm) were cut with rotary microtome, stained with hematoxylin-eosin, in a jar for 2-20 minutes. The blue staining of the hematoxylin is changed to red by the action of acid. Blue color is regained by washing in alkaline, running tap water for at least 5 minutes. Then, stained in 1% aqueous eosin for 1-3 minutes excess stain was washed under running tap water for 2-3 minutes and observed under microcopic for histopathological changes.

The histopathological images are shown in Fig.2

Identification of active compound

The treatment with physcion (100 mg/kg) for 90 days did not show any significant difference in femur length and weight compared to OVX control rats. The data are represented in Table 1.

Effect of physcion on femur length and weight

The treatment with physcion (100 mg/kg) for 90 days did not show any significant difference in femur length and weight compared to OVX control rats. The data are represented in Table 2.

Effect of physcion on serum biochemical parameters

The biochemical parameters correlated with the study as characterized by an increase in ALP and TRAP and fall in calcium level. This indicates an increase in the osteoblastic and osteoclastic activity, respectively, thereby showing that bone turnover, which takes place at a faster rate, may account for bone disorder [19]. In this study, groups treated with raloxifene and physcion (100 mg/kg) showed a suppressed ALP activity, which was highly significant (p<0.0001) when compared to OVX control rats. The serum calcium was also found to be reduced by an increase in ALP and TRAP and fall in calcium level. This indicates that bone turnover, which takes place at a faster rate, may account for bone disorder [19]. In this study, groups treated with raloxifene and physcion (100 mg/kg) showed a suppressed ALP activity, which was highly significant (p<0.0001) when compared to OVX control rats. The serum calcium was also found to be reduced.

The biochemical parameters correlated with the study as characterized by an increase in ALP and TRAP and fall in calcium level. This indicates an increase in the osteoblastic and osteoclastic activity, respectively, thereby showing that bone turnover, which takes place at a faster rate, may account for bone disorder [19]. In this study, groups treated with raloxifene and physcion (100 mg/kg) showed a suppressed ALP activity, which was highly significant (p<0.0001) when compared to OVX control rats. The serum calcium was also found to be reduced.

Effect of physcion on bone mechanical strength and BMD

BMD has been described as merely a surrogate measure of bone strength. However, microarchitectural properties are a newly emerged marker for the evaluation of the true impact of a treatment on the quality of trabecular bone [20]. The present data (Table 4) indicated that BMD and biomechanical strength were significantly (p<0.0001) reduced in OVX rats when compared to sham operated group, respectively.
In our study, the physcion (100 mg/kg) improved both mineral density (p<0.01) and bone strength (p<0.0001) to a normal value and which was comparable to the raloxifene-treated rats.

**Effect of physcion on bone ash weight and calcium content**

When compared to sham-operated rats, the OVX group exhibited a significant (p<0.0001) fall in ash weight and calcium content, respectively. Whereas the active component physcion (100 mg/kg) administered rats showed raise in its ash weight followed by improved calcium content (p<0.0001). The decreased bone mineral content was observed with ovariectomized rats and further it was evidenced by the reduction of total ash weight and ash calcium content, asserting its role in prevention of bone loss [21]. The data are represented in Table 5.

Human bone is rich in mineralized organic matrix and various bone cells. Osteoblasts are one among the bone cells that synthesize the organic matrix and regulate the bone formation, whereas osteoclasts cause bone resorption resulting in various problems associated with the skeletal system. The current approach mainly focuses to develop antosteoporotic drugs which are directed with bone resorption. In most postmenopausal women, there is a deficiency in the production of ovarian hormone and it has been recommended to improve bone loss. The hormone deficiency can also correlate to the plasma calcium levels which in turn lead to increased bone resorption [22]. The ovariectomized rat model is most commonly used in research on postmenopausal osteoporosis. Like humans, rats have a cancellous bone that undergoes remodeling once longitudinal growth has essentially ceased. In adult rats, OVX is followed by an increase in bone turnover associated with bone loss and a permanent deficit of bone mass at several skeletal sites including the vertebral bodies, the proximal femur, and the metaphysis of long bones such as distal femur and proximal tibia [23]. The previous studies have been reported on the plant *Morinda officinalis* and were found to have anthraquinones, which is a potent constituent responsible for estrogen-dependent bone healing activity and joint diseases. Seo et al. reported to have morinda root extracts both suppressor of bone resorption and an enhancer of bone formation in vivo and may have some favorable effects for preventing and treating the osteoporosis induced by sciatric neurectomy. Yan-Bin et al. also studied on *M. officinalis* root extract for the isolated anthraquinone derivatives and evaluated their antosteoporotic activity using osteoblast and osteoclastic cells [24].

In our study, the serum biochemical markers were found to possess significant changes in OVX control groups and protective effect was observed with treated groups. Among them, the bone formation marker ALP and resorption marker TRAP were found to have a significant effect. The serum calcium was also reduced with OVX, but the treatment had an effect on maintaining this level.

**CONCLUSION**

In this study, we have isolated and elucidated an anthraquinone derivative, physcion from ethanolic fruit extract of *M. citrifolia*, and evaluated for its antosteoporotic activity in ovariectomized rats. The results of this study indicated that isolated anthraquinone had a significant effect on bone resorption. Although, the inhibitory effect on bone resorption and the association of its action with female hormone is still unclear. Thus, further studies are necessary to elucidate the molecular mechanisms involved in the action, thereby provide a new approach for herbal drug development.

**ACKNOWLEDGMENT**

The authors are thankful to vision group of science and technology (VGST), Bengaluru, for funding this project, Dr. J. Saravanam, Principal and Dr. S. Mohan, Director, PES College of Pharmacy, Bengaluru, for supporting this work.

---

**Table 3: Effect of physcion on serum biochemical parameters**

| Serial number | Groups          | ALP (IU/L)     | Calcium (mg/dl) | TRAP (IU/L)  |
|---------------|----------------|----------------|-----------------|--------------|
| 1             | Sham operated  | 175.6±17.32    | 6.64±0.512      | 1.65±0.015   |
| 2             | OVX control    | 66.8±6.63***   | 5.16±0.73***    | 2.53±0.014** |
| 3             | Raloxifene (5.4 mg/kg) | 204.5±0.035*** | 7.19±0.23**    | 1.62±0.016***|
| 4             | Physcion (100 mg/kg) | 153.2±5.11*** | 7.37±0.254***  | 2.45±0.512** |

Values are in mean±SEM (n=6). One-way ANOVA followed by Tukey-Kramar multiple comparison test *p<0.05, **p<0.01, ***p<0.0001. Normal versus OVX control, *OVX control versus treated groups. SEM: Standard error of the mean, OVX: Ovariectomy, ALP: Alkaline phosphatase, TRAP: Tartrate resistant acid phosphatase.

**Table 4: Effect of physcion on bone impact test and bone mineral density**

| Serial number | Groups          | Force at break (N) | BMD (wt/ml)    |
|---------------|----------------|--------------------|----------------|
| 1             | Sham operated  | 105.2±1.92         | 0.86±0.013     |
| 2             | OVX control    | 83.5±4.42***       | 0.82±0.015***  |
| 3             | Raloxifene (5.4 mg/kg) | 127.2±3.78***     | 0.90±0.005***  |
| 4             | Physcion (100 mg/kg) | 100.3±0.96***     | 0.84±0.014***  |

Values are in mean±SEM (n=6). One-way ANOVA followed by Tukey-Kramar multiple comparison test *p<0.05, **p<0.01, ***p<0.0001. Normal versus OVX control, *OVX control versus treated groups. SEM: Standard error of the mean, OVX: Ovariectomy, BMD: Bone mineral density.

**Table 5: Effect of physcion on bone ash weight and mineral content**

| Serial number | Groups          | Ash weight (g) | Calcium (mg/dl) |
|---------------|----------------|----------------|-----------------|
| 1             | Sham operated  | 0.58±0.01      | 11.28±0.41      |
| 2             | OVX control    | 0.36±0.014***  | 7.93±0.22***    |
| 3             | Raloxifene (5.4 mg/kg) | 0.60±0.014***  | 11.46±0.34***   |
| 4             | Physcion (100 mg/kg) | 0.41±0.014***  | 9.44±0.45***    |

Values are in mean±SEM (n=6). One-way ANOVA followed by Tukey-Kramar multiple comparison test *p<0.01, **p<0.0001. Normal versus OVX control, *OVX control versus treated groups. SEM: Standard error of the mean, OVX: Ovariectomy.
REFERENCES

1. Chitme HR, Muchandi IS, Burli SC. Effect of Asparagus racemosus Willd root extract on ovariectomized rats. J Nat Prod 2009;2:16-23.

2. Thokchom S, Chhugani M. A study to find out the prevalence for osteoporosis and osteopenia in pre and post-menopausal women in India: A cross sectional study. IJSR 2015;4(10):270-3.

3. Malhotra N, Mithal A. Osteoporosis in Indians. Indian J Med Res 2008;127(3):263-8.

4. Zeng GF, Zhang ZY, Lu L, Xiao DQ, Xiong CX, Zhao YX, et al. Protective effects of Polygonatum sibiricum polysaccharide on ovariectomy-induced bone loss in rats. J Ethnopharmacol 2011;136(1):224-9.

5. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7(9):1005-10.

6. Dipiro JT, Rotschafer JC, Kolesar JM, Wells BG. Pharmacotherapy, Principles and Practice. New York: McGraw-Hill Companies, Inc.; 2008.

7. NOF. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporotic Foundation; 2010.

8. OECD. Guideline for Testing of Chemicals. Acute Oral Toxicity, 420 Adopted. Paris: OECD; 2001.

9. OECD. Guideline for Testing of Chemicals. Acute Oral Toxicity, 420 Adopted. Paris: OECD; 2001.

10. Shivakumar K, Mukund H, Rabin P. Evaluation of antiosteoporotic activity of root extract of Rubia cordifolia in ovariectomized rats. Int J Drug Dev Res 2012;4(3):163-72.

11. Srikanth P, Nagarajappa SH, Viswanatha GL, Handral M, Subbanna R, Srinath R, et al. Antiosteoporotic activity of methanolic extract of an Indian herbal formula NR/CA/06 in ovariectomized rats. JCIM 2011;9(10):1125-32.

12. Shivakumar K, Mukund H, Rabin P. Evaluation of antiosteoporotic activity of root extract of Rubia cordifolia in ovariectomized rats. Int J Drug Dev Res 2012;4(3):163-72.

13. WHO. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva: WHO; 1998.

14. Kumar R, Murugananthan G, Nandakumar K, Talwar S. Isolation of anxiolytic principle from ethanolic root extract of Cardiospermum halicacabum. Phytomedicine 2011;18(2-3):219-23.

15. Khajuria DK, Razdan R, Mahapatra DR. Description of a new method of ovariectomy in female rats. Rev Bras Reumatol 2012;52(3):462-70.

16. Shivakumar K, Mukund H, Rabin P. Evaluation of antiosteoporotic activity of root extract of Rubia cordifolia in ovariectomized rats. Int J Drug Dev Res 2012;4(3):163-72.

17. Srikanth P, Nagarajappa SH, Viswanatha GL, Handral M, Subbanna R, Srinath R, et al. Antiosteoporotic activity of methanolic extract of an Indian herbal formula NR/CA/06 in ovariectomized rats. JCIM 2011;9(10):1125-32.

18. Hall LE, Shirley RB, Bakalli RI, Aggrey SE, Pesti GM, Edwards HM Jr. Power of two methods for the estimation of bone ash of broilers. Poult Sci 2003;82(3):414-8.

19. Annie S, Prabhu RG, Malini S. Activity of Wedelia calendulacea Less. in post-menopausal osteoporosis. Phytomedicine 2006;13(1-2):43-8.

20. Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK, et al. Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol 2011;134(2):334-8.

21. Liang H, Yu F, Tong Z, Huang Z. Effect of Cistanches herba aqueous extract on bone loss in ovariectomized rat. Int J Mol Sci 2011;12(8):5060-9.

22. Soni HK, Kandachia JM, Jani DK, Patel GR. Pharmacological investigation of bonton capsule for anti-osteoporotic activity in ovariectomized rat. Int J Pharm Phytopharmacol Res 2013;3(1):52-6.

23. WHO. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva: WHO; 1998.

24. Wu YB, Zheng CJ, Qin LP, Sun LN, Han T, Jiao L, et al. Antiestrogenic activity of antracquinones from Morinda officinalis on osteoblasts and osteoclasts. Molecules 2009;14(1):573-83.